The establishment of Qiqi Biomedical is not only a technological innovation,
It is also a profound commitment to the value of life.
The establishment of Qiqi Biomedical
Not just a technological innovation,
It's also a
A profound commitment to the value of life.
We offer more than just cells; we offer a pathway to clinical application.
We provide comprehensive technical support and professional services, from cell bank establishment to clinical trial execution.
Self-built cell bank system
Establish a Master/Working Cell Bank that meets international standards, and manage the entire process of cell sourcing, quality assessment, and cryopreservation to provide a stable and traceable cell source for clinical trials and new drug development.
Clinical pipeline focused on anti-aging
With frailty syndrome as the main focus of the first phase of development, the dosage, dosing strategy and evaluation indicators were designed according to clinical needs, and FDA IND approval was obtained in June 2026.
A one-stop technology partner from concept to case submission.
We assist pharmaceutical companies and medical institutions in selecting indications, conducting feasibility assessments, and planning development strategies. We provide process development (CMC), quality management, and regulatory consulting services, accompanying our partners all the way to clinical trial execution and subsequent expansion.
Collaboration modes designed for different roles
For medical institutions and clinical teams
Looking to launch clinical trials in the cell field or establish an in-hospital cell therapy model? Chi-Chi Biotech provides integrated support for cell formulation, trial design, and quality control.
pharmaceutical companies and biotechnology companies
Whether you're looking to develop new indications or strengthen your existing product line, we offer a one-stop solution from cell bank architecture and process development to FDA IND document preparation.
For investors and industry partners
Want to learn about Qiqi Biomedical's pipeline layout, development timeline, and collaboration opportunities? Feel free to contact us to discuss the next steps in regenerative medicine.
Development Timeline and Key Milestones
2025
- Qi-Chi Biotech officially established
- Completed the establishment of core MSC cell bank architecture and quality standards
- Initiated preclinical research and trial design for asthenia
- Completed key preclinical validation and process optimization
2026
In June 2026, we obtained the first FDA IND approval for an MSC cell product.
2026/7~2027
- Collaborate with partner medical institutions to plan clinical trial designs.
- Initiate Phase I/II clinical trials based on IND review results.
- Continuously evaluate indications for other anti-aging fields.
- Advance the development and commercialization of stem cell exosome cosmetics.
